Improving time-to-result: head-to-head comparison of three rapid AST systems for Gram-negative bacteremia, including the newly developed VITEK REVEAL
Journal of Clinical Microbiology · 12.11.2025 · 63 (11)
DOI: 10.1128/jcm.01050-25 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Clinical Microbiology, erschienen am 12.11.2025. Verfasst von Damiano Squitieri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy. Hauptthemen laut MEDLINE: Bacteremia, Gram-Negative Bacterial Infections, Anti-Bacterial Agents, Gram-Negative Bacteria. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission.
Abstract (Originalsprache)
Early antimicrobial susceptibility testing (AST) in Gram-negative (GN) bloodstream infections is critical to guide appropriate therapy. This study evaluated three rapid AST (RAST) systems—VITEK REVEAL, direct-from-blood-culture VITEK 2 (VITEK 2-RAST), and EUCAST disk diffusion (DD-RAST)—using 220 prospectively collected GN-positive blood cultures (GN-PBCs). A total of 18 GN species were tested, including Enterobacterales , Acinetobacter baumannii , and Pseudomonas aeruginosa , against 25 antibiotics, four of which were next-generation β-lactam/β-lactamase inhibitor (BL/BLI) antibiotics. Reference broth microdilution was used for comparison. The VITEK REVEAL assay showed 97.1% essential agreement (EA), −7.7 bias, and 98.3% categorical agreement (CA) across 3,603 organism/antibiotic combinations. The VITEK 2-RAST assay showed 96.2% EA, −10.4 bias, and 98.4% CA across 3,941 combinations. The DD-RAST assay showed 98.2% CA across 2,388 combinations. Among 164 GN-PBCs tested with all three assays, EA rates were 97.5% for VITEK REVEAL and 96.3% for VITEK 2-RAST, with bias values of −7.1 and −6.9, respectively. Across all three assays, the CA rate was ≥98.2%, and very major error (VME) rates were ≤1.8%. Mean time-to-result (TTR) was significantly shorter with VITEK REVEAL (6 h 32 min) compared to VITEK 2-RAST (13 h 51 min) and the fixed 8 h of DD-RAST. In resistant organisms, VITEK REVEAL produced significantly faster results than in susceptible or intermediate ones, including BL/BLI antibiotics. A. baumannii yielded the shortest TTR, with no observed VME. These results support the use of RAST directly on GN-PBCs, with VITEK REVEAL emerging as a particularly promising option for rapid and accurate testing. IMPORTANCE This study is the first to conduct a direct comparison of three rapid antimicrobial susceptibility testing (RAST) systems—VITEK REVEAL, VITEK 2-RAST, and DD-RAST—on a large, prospectively collected cohort of Gram-negative-positive blood cultures (GN-PBCs). The data offer valuable insights for laboratories evaluating RAST implementation, especially in EUCAST-based contexts. Among the systems tested, VITEK REVEAL stood out for its combination of rapid turnaround and high accuracy, including for antibiotic-resistant organisms and β-lactam/β-lactamase inhibitor (BL/BLI) antibiotics. These findings underscore the potential of RAST systems to deliver timely and reliable susceptibility results directly from GN-PBCs, thereby supporting more effective antimicrobial stewardship and clinical decision-making. However, the real-world impact will also depend on how well these systems integrate into routine workflows, as seamless implementation can directly affect time-to-result (TTR)—an essential element in optimizing the management of GN-bloodstream infection (BSI).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy.
- Dipartimento di Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
- Unità Operativa "Medicina di Precisione in Microbiologia Clinica", Direzione Scientifica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
ORCID-Profile: Maurizio Sanguinetti, Brunella Posteraro
Förderung
- European Commission
Zitieren
APA
Squitieri, D., Menchinelli, G., Magrì, C., D'Inzeo, T., Fiori, B., Cacaci, M., Sanguinetti, M., De Angelis, G., & Posteraro, B. (2025). Improving time-to-result: head-to-head comparison of three rapid AST systems for Gram-negative bacteremia, including the newly developed VITEK REVEAL. Journal of Clinical Microbiology, 63(11). https://doi.org/10.1128/jcm.01050-25
Vancouver
Squitieri D, Menchinelli G, Magrì C, D'Inzeo T, Fiori B, Cacaci M, et al. Improving time-to-result: head-to-head comparison of three rapid AST systems for Gram-negative bacteremia, including the newly developed VITEK REVEAL. Journal of Clinical Microbiology. 2025;63(11). doi:10.1128/jcm.01050-25
BibTeX
@article{Squitieri2025,
author = {Squitieri, Damiano and Menchinelli, Giulia and Magrì, Carlotta and D'Inzeo, Tiziana and Fiori, Barbara and Cacaci, Margherita and Sanguinetti, Maurizio and De Angelis, Giulia and Posteraro, Brunella},
title = {Improving time-to-result: head-to-head comparison of three rapid AST systems for Gram-negative bacteremia, including the newly developed VITEK REVEAL},
journal = {Journal of Clinical Microbiology},
year = {2025},
volume = {63},
number = {11},
doi = {10.1128/jcm.01050-25}
}
EUVIMED